Merus announces publication of abstract on Petosemtamab at ASCO

Merus N.V. announced the publication of an abstract regarding petosemtamab in combination with pembrolizumab on the 2024 American Society of Clinical Oncology(R) (ASCO(R)) Annual Meeting website. The abstract presents interim clinical data from a cohort of 26 patients enrolled as of the abstract cutoff date, evaluating the combination in first line (1L) recurrent/metastatic (r/m) head and neck squamous cell carcinoma for presentation at the 2024 ASCO(R) Annual Meeting taking place in Chicago, May 31-June 4, 2024. “We believe petosemtamab continues to demonstrate potential best in class safety and efficacy in head and neck cancer. We are encouraged with the well tolerated safety profile of the combination of petosemtamab and pembrolizumab, particularly with a low rate of Grade 3 or greater adverse events, and a low rate of infusion-related reactions observed,” said Bill Lundberg, CEO. “These data in the abstract provide encouraging efficacy albeit from an early cutoff date, with less mature data. And we look forward to our conference call, Tuesday May 28, to discuss the more mature clinical update from a later cutoff date where the response rate further improved.”